MaterialsRadebeul, GermanyFounded 2004· One of 977 Materials companies tracked by AMPulse
Develops and manufactures 3D-printed resorbable calcium phosphate scaffolds and bone cements for patient-specific bone regeneration implants, enabling minimally invasive treatment of bone defects.
CEO / Founder
Sascha Heinemann
Team Size
11-50
Stage
Acquired
Total Funding
$13.5M
Latest Round
Acquired
Key Investors
Nivalis Group
Technology & Products
Key Products
INNOTERE Paste-CPC; INNOTERE 3D Scaffolds; Plotter-Paste-CPC; Cell Culture Scaffolds; Veterinary bone substitutes; Hydroxyapatite powders
Technological Advantage
Patented paste formulation and 3D printing process enable precise control over scaffold architecture and resorption rates, protected by 59 patents in tissue engineering and 3D bioprinting.
Differentiation
Value Proposition
Reduces bone implant production time from weeks to days by enabling direct 3D printing of patient-specific scaffolds from CT data, with materials that mimic natural bone structure and resorb over time.
How They Differentiate
Focuses exclusively on calcium phosphate-based biomaterials for bone regeneration, unlike broader 3D printing companies; offers certified Class III medical devices with MDR 2017/745 certification.
Market & Competition
Target Customers
Hospitals, orthopedic surgeons, veterinary clinics, biomaterials research institutions
Industry Verticals
Medical Devices; Orthopedics; Veterinary Medicine; Biomaterials Research
Competitors
Zimmer Biomet, Stryker, Medtronic, Johnson & Johnson, Geistlich Pharma AG, Xtant Medical
Growth & Milestones
Major Milestones
Founded in 2004; ISO 9001:2008 and ISO 13485:2012 certification in 2008; Moved to Radebeul in 2012; Acquired by Heraeus Medical in early 2025
Notable Customers
Biomaterials research community; Veterinary clinics; Orthopedic hospitals
InnoTERE occupies a narrow but defensible niche within medical additive manufacturing: 3D-printed resorbable calcium phosphate scaffolds and bone cements for patient-specific bone regeneration. Unlike broader orthopedic implant makers that rely on metal or polymer devices, InnoTERE focuses exclusively on calcium phosphate biomaterials that mimic natural bone structure and resorb over time, eliminating the need for secondary removal surgeries.
The core technology is a proprietary calcium phosphate cement paste that enables low-temperature 3D printing via material extrusion (MEX). The process produces nanocrystalline hydroxyapatite scaffolds with customizable porosity and shape, directly from patient CT data. This reduces implant production time from weeks to days. The company's product line includes INNOTERE Paste-CPC, INNOTERE 3D Scaffolds, and veterinary bone substitutes, all protected by a portfolio of 59 patents in tissue engineering and bioprinting.
Target customers include hospitals, orthopedic surgeons, veterinary clinics, and biomaterials research institutions. The company holds ISO 13485:2012 certification and MDR 2017/745 certification for Class III medical devices, a regulatory barrier that limits direct competition from generalist 3D printing firms. In early 2025, InnoTERE was acquired by Heraeus Medical, a move that provides distribution scale and clinical credibility.
The primary competitive risk is that larger orthopedic players such as Zimmer Biomet, Stryker, and Medtronic could develop in-house resorbable implant capabilities, though InnoTERE's proprietary paste formulation and regulatory certifications create meaningful switching costs. The company's R&D partnership with Filgen and BMBF-funded MBC project suggest ongoing investment in next-generation biomaterials.